Patents Examined by Carla J. Myers
  • Patent number: 10501804
    Abstract: The present disclosure provides for and relates to the identification of novel biomarkers for diagnosis and prognosis of prostate cancer or the biochemical reoccurrence of prostate cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal prostate tissue, as set forth.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: December 10, 2019
    Assignees: HudsonAlpha Institute for Biotechnology, Board of Trustees of the Leland Stanford Junior University
    Inventors: Richard M. Myers, James D. Brooks, Marie K. Kirby
  • Patent number: 10501803
    Abstract: The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: December 10, 2019
    Assignees: MAX-PLANCK GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN
    Inventors: Guillermo Barreto, Aditi Mehta, Indrabahadur Singh, Marten Szibor, Rajkumar Savai, Werner Seeger, Thomas Braun, Andreas Günther, Marcus Krüger
  • Patent number: 10487361
    Abstract: The invention provides to methods for diagnosing eye-length related disorders, including myopia. The invention also provides methods for treating and limiting eye-length related disorders, including myopia. In addition, the invention provides certain haplotypes associated with eye-length related disorders, including myopia and Bornholm Eye Disease.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: November 26, 2019
    Assignee: University of Washinton Through its Center for Commercialization
    Inventors: Jay Neitz, Maureen Neitz
  • Patent number: 10487365
    Abstract: Described herein are biomarkers for HPV-associated pre-cancers and cancers such as cervical cancer and cervical intraepithelial neoplasia. The RNA binding protein (RBP) and long-noncoding RNA (lnc-RNA) biomarkers can be detected and used to diagnose HPV-associated pre-cancers and cancers. In addition, early diagnosis of HPV-associated pre-cancers and cancers can facilitate therapeutic intervention in patients, particularly in the pre-cancer stage which can delay or prevent progression to cancer.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: November 26, 2019
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Zhi-Ming Zheng, Junfen Xu, Jun Zhu, Yanqin Yang, Xiaohong Wang
  • Patent number: 10465250
    Abstract: The present invention relates to pancreatic cancer, and more particularly to the survival prognosis of a patient suffering from pancreatic cancer. The invention also aims to determine the suitability of said patient to receive a treatment for pancreatic cancer, in particular a treatment with gemcitabine. The invention also concerns a method for monitoring the effectiveness of a treatment for pancreatic cancer, and advantageously a treatment with gemcitabine, by implementing the method.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: November 5, 2019
    Assignee: ACOBIOM
    Inventor: David Piquemal
  • Patent number: 10435758
    Abstract: The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: October 8, 2019
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
  • Patent number: 10428391
    Abstract: Methods and kits for triaging a human papillomavirus (HPV)-positive woman into colposcopy are disclosed. The methods comprise determining the promoter methylation level of the promoter regions of a group of genes (e.g., viral and host genes) that exhibit increased promoter methylation in women having CIN2+ lesions as compared to women having no intraepithelial lesions or malignancy (NILM).
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: October 1, 2019
    Assignee: The Johns Hopkins University
    Inventors: Rafael Guerrero-Preston, David Sidransky
  • Patent number: 10407740
    Abstract: Oligomers useful for determining the presence of Trichomonas vaginalis in a test sample.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: September 10, 2019
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Barbara Susan Weinbaum, Janel M. Dockter, Astrid R. W. Schroder
  • Patent number: 10400289
    Abstract: The present invention provides a method for detecting a target nucleic acid that comprises a step of providing a sample; contacting the sample with a polynucleotide probe comprising a first sequence and a second sequence complementary to the target nucleic acid; and adding a nuclease for cleaving the second sequence of the polynucleotide probe. The present invention further provides a polynucleotide probe for detecting a target nucleic acid that comprises a first sequence and a second sequence complementary to the target nucleic acid. Moreover, the present invention provides a kit for detecting a target nucleic acid.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: September 3, 2019
    Assignee: National Taiwan University
    Inventors: Ja-An A. Ho, Amily F. Jou, Yen-Chuan Ou, Shian-Shiang Wang, Itamar Willner, Shih-Lan Hsu
  • Patent number: 10400291
    Abstract: The present disclosure describes a method for identifying a strain or species of bacteria using a single locus sequence typing technique. The single locus useful in the method is the promoter region of the 16S rRNA operon. The method is useful to identify infectious bacteria in a subject, to identifying contaminants in a food source, as well as strain typing and genetic fingerprinting of bacterial families.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: September 3, 2019
    Assignee: The Regents of the University of Michigan
    Inventors: John LiPuma, Theodore Spilker
  • Patent number: 10400290
    Abstract: The present invention relates to methods for predicting, diagnosing and monitoring cancer. The methods comprise obtaining biological samples, extracting mitochondrial DNA (mtDNA) from the samples, quantifying mitochondrial DNA mutation in the sample and comparing the level of mtDNA mutation with a reference value. The methods of the invention may also be effective in screening for new therapeutic agents and treatment regimes, and may also be useful for monitoring the response of a subject to a preventative or therapeutic treatment.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: September 3, 2019
    Assignee: MDNA Life Sciences, Inc.
    Inventors: Ryan Parr, Jennifer Creed, Kerry Robinson, Andrea Maggrah, Katrina Maki, Gabriel Dakubo, Brian Reguly, Andrew Harbottle, Jude Alexander
  • Patent number: 10392671
    Abstract: A method of examining a water supply for microbial contamination involves contacting a water supply with a novel reagent having high specificity for a Legionella microbial species, wherein said reagent does not cross-react, or minimally cross-reacts, with a microbial species other than Legionella. The method further involves detecting, or measuring, a contaminating concentration of a Legionella species in the water supply. Useful reagents comprise at least one nucleotide sequence primer comprising a primer sequence selected from SEQ ID NO: 3-10 or a combination of such primer sequences. The increased specificity of such reagents permits more sensitive detection of microbial contamination.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: August 27, 2019
    Assignee: Dow Global Technologies LLC
    Inventors: Paul O. Schook, Bei Yin
  • Patent number: 10385398
    Abstract: This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: August 20, 2019
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Hakon Hakonarson, Yun Rose Li, Brendan Keating
  • Patent number: 10385404
    Abstract: This invention relates to a kit for detecting NRAS gene mutation, and this kit can be used to detect cancer-related NRAS gene mutation. The said kit comprises: (1) the internal reference detection reagent, which includes the internal reference gene specific primers, internal reference gene specific probes and dNTP solution; (2) the NRAS mutation detection reagent, which includes the NRAS gene mutant type specific primers, NRAS gene mutant type specific probes, internal control gene specific primers, internal control gene specific probes and dNTP solution; (3) the Taq DNA polymerase; and (4) the NRAS positive quality control.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: August 20, 2019
    Assignee: Jiaxing ACCB Diagnositc Ltd.
    Inventors: Minli Mo, Hui Li, Zhao Chen, Feng Ding, Jun Li
  • Patent number: 10378065
    Abstract: The disclosure concerns a prognostic method for determining at least one, or a combination, of the following: time to first treatment, response to treatment or overall survival for a patient presenting with a disease including or characterized by telomere shortening, including an assessment of the longest mean telomere length at which telomere end-end fusion events can be detected and then a determination of the mean telomere length in the fusogenic range (i.e. the range below that mean telomere length at which telomere end-end fusion events can be detected) and the subsequent use of the mean telomere length in the fusogenic range as a prognostic indicator.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: August 13, 2019
    Assignee: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED
    Inventors: Duncan Baird, Chris Pepper, Christopher Fegan
  • Patent number: 10370717
    Abstract: The present invention provides for methods of measuring levels of micro RNAs for the diagnosis, treatment and/or monitoring the progression of post-traumatic stress disorder (PTSD) or traumatic brain injury (TBI) in a subject having or suspected of having PTSD and/or TBI. The methods, in general comprise measuring levels of at least one of miR-142-5p, miR-19b, miR-1928, miR-223-3p, miR-322*, miR-324, miR-421-3p, miR-463* and miR-674* is a sample from a subject suffering from or suspected of having PTSD and/or TBI.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: August 6, 2019
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Radha K. Maheshwari, Nagaraja S. Balakathiresan, Manish Bhomia, Raghavendar Chandran
  • Patent number: 10364470
    Abstract: The invention described in the application relates to a long non-coding RNA expressed in cancer. The invention thus provides methods and compositions for evaluating levels of the long non-coding RNA to assess the aggressiveness of a cancer and for modulating levels of the long non-coding RNA.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: July 30, 2019
    Assignee: The Regents of the University of California
    Inventors: Terumi Kohwi-Shigematsu, Yoshinori Kohwi, Ellen C. Ordinario, Michael A. Balamotis, Hye-Jung Han
  • Patent number: 10344331
    Abstract: Compositions and methods useful for the diagnosis and treatment of juvenile idiopathic arthritis are disclosed.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: July 9, 2019
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Terri H. Finkel, Haitao Zhang, Hakon Hakonarson
  • Patent number: 10344315
    Abstract: A method of retrieving fetal cells from an endocervical sample by removing the mucus from the endocervical sample by disassociating fetal cells and maternal cells in the endocervical sample; and isolating disassociated fetal cells from other cells in the endocervical sample. Also provided is a method of retrieving fetal cells from an endocervical sample, by obtaining a mixture of disassociated cells prepared by the above method, treating the cells with a fetal-specific antibody, identifying cells that have bound to the fetal-specific antibody, and isolating the identified cells. The disassociated cell prepared by the above method can be analyzed and used for a variety of purposes including, but not limited to, the identification of fetal cells among cervical cells, determination of fetal cell density to predict high risk pregnancy, genetic analysis of fetal cells, and determination of growth factor or other biomarker expression to predict obstetrical disorders.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: July 9, 2019
    Assignee: Wayne State University
    Inventors: D. Randall Armant, Michael P. Diamond
  • Patent number: 10330680
    Abstract: Methods of isolating and assaying fetal extravillous trophoblast cells, including assays of RNA of the fetal extravillous trophoblast cells according to aspects of the disclosure include obtaining a maternal endocervical sample containing fetal extravillous trophoblast cells from a pregnant subject; fixing the maternal endocervical sample in an aldehyde fixative, removing fetal extravillous trophoblast cells from the maternal endocervical sample thereby producing isolated extravillous trophoblast cells, isolating and assaying RNA from the fetal extravillous trophoblast cells.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: June 25, 2019
    Assignee: Wayne State University
    Inventors: D. Randall Armant, Sascha Drewlo